RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.
Retrieved on:
Montag, April 3, 2023
Epilepsy, GABA, Anticonvulsant, Tremor, GABAergic, OTC Markets Group, DRS, KPP, University of Wisconsin–Milwaukee, KRM, Essential tremor, Pain, Patient, University, Blood, Neuropathic pain, Indiana University–Purdue University Indianapolis, Irena Kosmowska, Drug discovery, CFO, ACS Omega, IND, RespireRx, Pharmaceutical industry
Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
Key Points:
- Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
- In addition KRM-II-81 is active in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.
- 385:50-61 document the preclinical effects and tolerability of structural analogs of KRM-II-81.
- In established rat models predicting efficacy in essential tremor and in tremor associated with Parkinson’s Disease, MP-III-024 was an effective anti-tremor compound.